Increasing rates of buprenorphine diversion in the United States, 2002 to 2019
| Autor: | Zachary R Margolin, Stevan G. Severtson, Steven P. Kurtz, Mance E Buttram |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Prescription Drug Diversion
Epidemiology Population Law Enforcement Surveys and Questionnaires medicine Humans Pharmacology (medical) Medical prescription education education.field_of_study business.industry Opioid use disorder Drug diversion respiratory system medicine.disease Quarter (United States coin) Opioid-Related Disorders United States Buprenorphine Analgesics Opioid Gradual increase business human activities Demography medicine.drug |
| Zdroj: | Pharmacoepidemiology and drug safetyREFERENCES. 30(11) |
| ISSN: | 1099-1557 |
| Popis: | PURPOSE Recent reports suggest that buprenorphine is being diverted and used non-medically. However, no apparent studies have reported national-level data on buprenorphine diversion. METHODS Case report data were drawn from a quarterly survey of prescription drug diversion completed by a national sample of law enforcement and regulatory agencies who engage in drug diversion investigations. Quarterly rates of buprenorphine diversion per 100 000 population and 100 000 prescriptions dispensed were calculated for the period 2002 through 2019. Population-based diversion rates were also calculated by U.S. region. RESULTS In total, 9670 cases of diverted buprenorphine were reported across all 50 states and the District of Columbia during the study period. Buprenorphine diversion rates, per 100 000 population, were characterized by an accelerating increase over time; increases in diversion rates from 1st quarter 2002 through 4th quarter 2006 were not statistically significant, yet from 1st quarter 2007 through 4th quarter 2019, the rate of diversion cases increased by 0.0067 cases per 100 000 per quarter (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text